Research programme: oxytocin antagonists - GlaxoSmithKline
Latest Information Update: 19 Apr 2011
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action Oxytocin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Preterm labour
Most Recent Events
- 02 Oct 2006 Preclinical trials in Preterm labour in United Kingdom (PO)